FDA Approves Human Genome (HGSI), Glaxo Drug Benlysta

The first new drug to treat Lupus in over 50 years won U.S. approval on Wednesday. Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline PLC (GSK) said that the U.S. Food and Drug Administration [FDA] has approved ‘Benlysta’, an injectable drug designed to relieve flare-ups and pain caused by the disabling disease. Benlysta was discovered by [...]

VFC submits: The long wait is over for Human Genome Sciences (HGSI), partner GlaxoSmithKline (GSK) and investors of both companies as the FDA announced on Wednesday that Benlysta has been granted approval for the treatment of lupus.

Todd Johnson submits:Human Genome Sciences (HGSI) is finally coming to market with the full FDA approved medication. The company's early years hype, and later years near-death stock experience, can all be viewed in perspective.

Pharmalot submits: On Tuesday, an FDA advisory panel will review the first new treatment for lupus in decades. And the early indications are that Benlysta, which is being developed by Human Genome Sciences (HGSI), will win an endorsement. At least that’s how some Wall Street analysts are interpreting the FDA briefing documents filed Friday morning, even though the stock is trading down.